LEGEND BIOTECH CORP-ADR
LEGNNASDAQTrading Snapshot
- Day Range
- $18.55 – $19.15
- 52-Week Range
- $16.24 – $37.50
- Volume
- $2.31B
- Avg Volume
- $1.80B
- Shares Outstanding
- 184.9M
- Next Earnings
- Dec 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.03B
- Last Q Revenue
- $388M
- P/E Ratio
- -37.6
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.49
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.0%
Why Investors Own LEGN
- ✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LEGEND BIOTECH CORP-ADR
LEGN
StockOtter · stockotter.spaceAbout LEGEND BIOTECH CORP-ADR
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company, MarketBeat.com reports. One in
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appoin
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safety st